Unicycive Therapeutics (UNCY) Share-based Compensation (2020 - 2026)
Unicycive Therapeutics (UNCY) reported Share-based Compensation of $754000.0 for Q1 2026, up 33.93% on a YoY basis from $563000.0 in Q1 2025, and down 3.08% quarter-over-quarter from $778000.0 in Q4 2025.
Unicycive Therapeutics (UNCY) Share-based Compensation (2020 - 2026) Analysis & Trends
Unicycive Therapeutics has reported Share-based Compensation for 7 years, with the latest figure at $754000.0 in Q1 2026.
- For the quarter ending Q1 2026, Share-based Compensation rose 33.93% year-over-year to $754000.0; the trailing twelve-month figure through Mar 2026 stood at $2.8 million (up 18.44% YoY), and the FY2025 full-year result was $2.6 million, up 12.38% from the prior year.
- Share-based Compensation for Q1 2026 stood at $754000.0, down from $778000.0 in the prior quarter.
- The five-year high for Share-based Compensation was $929000.0 in Q3 2023, with the low at $144000.0 in Q2 2022.
- Historically, Share-based Compensation has averaged $494647.1 across 5 years, with a median of $563000.0 in 2025.
- Annual changes were most pronounced in 2022 — Share-based Compensation tumbled 51.02% — and 2024, when it jumped 345.14%.
- Unicycive Therapeutics' Share-based Compensation stood at $197000.0 in 2022, then soared by 179.19% to $550000.0 in 2023, then rose by 5.82% to $582000.0 in 2024, then soared by 33.68% to $778000.0 in 2025, then fell by 3.08% to $754000.0 in 2026.
- The last three Share-based Compensation figures came in at $754000.0 (Q1 2026), $778000.0 (Q4 2025), and $729000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 814,307.08 Bn | 814,307.05 Bn | - | - |
| 2 | Belite Bio | 55,320.00 Bn | 55,320.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,149.72 Bn | 17,149.72 Bn | - | - |
| 4 | Legend Biotech | 3,590.00 Bn | 3,589.71 Bn | 242.10 Mn | - |
| 5 | Akari Therapeutics | 1,650.72 Bn | 1,650.72 Bn | - | 305,000.00 |
| 6 | Evaxion A | 1,522.09 Bn | 1,522.07 Bn | - | - |
| 7 | Psyence Biomedical | 229.39 Bn | 229.38 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 113.09 Bn | 105.85 Bn | 2.59 Bn | 166.40 Mn |
| 9 | Abivax | 90.15 Bn | 90.15 Bn | - | 26.47 Mn |
| 10 | Unicycive Therapeutics | 174.05 Mn | 119.47 Mn | - | 754,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 754,000.00 |
| Mar 31, 2026 | 754,000.00 |
| Dec 31, 2025 | 778,000.00 |
| Dec 31, 2025 | 778,000.00 |
| Sep 30, 2025 | 729,000.00 |
| Sep 30, 2025 | 729,000.00 |
| Jun 30, 2025 | 571,000.00 |
| Jun 30, 2025 | 571,000.00 |
| Mar 31, 2025 | 563,000.00 |
| Mar 31, 2025 | 563,000.00 |
| Dec 31, 2024 | 582,000.00 |
| Dec 31, 2024 | 582,000.00 |
| Sep 30, 2024 | 605,000.00 |
| Sep 30, 2024 | 605,000.00 |
| Jun 30, 2024 | 641,000.00 |
| Jun 30, 2024 | 641,000.00 |
| Mar 31, 2024 | 522,000.00 |
| Mar 31, 2024 | 522,000.00 |
| Dec 31, 2023 | 550,000.00 |
| Dec 31, 2023 | 550,000.00 |